ONCODES.PREC.MED. EO-34 (F:ZR8) — Market Cap & Net Worth
Market Cap & Net Worth: ONCODES.PREC.MED. EO-34 (ZR8)
ONCODES.PREC.MED. EO-34 (F:ZR8) has a market capitalization of $8.12 Million (€6.94 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #27354 globally and #2375 in its home market, demonstrating a -2.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ONCODES.PREC.MED. EO-34's stock price €0.41 by its total outstanding shares 18122138 (18.12 Million).
ONCODES.PREC.MED. EO-34 Market Cap History: 2022 to 2026
ONCODES.PREC.MED. EO-34's market capitalization history from 2022 to 2026. Data shows change from $38.03 Million to $8.64 Million (-34.36% CAGR).
ONCODES.PREC.MED. EO-34 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ONCODES.PREC.MED. EO-34's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ZR8 by Market Capitalization
Companies near ONCODES.PREC.MED. EO-34 in the global market cap rankings as of May 5, 2026.
Key companies related to ONCODES.PREC.MED. EO-34 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ONCODES.PREC.MED. EO-34 Historical Marketcap From 2022 to 2026
Between 2022 and today, ONCODES.PREC.MED. EO-34's market cap moved from $38.03 Million to $ 8.64 Million, with a yearly change of -34.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €8.64 Million | +13.02% |
| 2025 | €7.65 Million | -50.00% |
| 2024 | €15.30 Million | -58.14% |
| 2023 | €36.55 Million | -3.90% |
| 2022 | €38.03 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of ONCODES.PREC.MED. EO-34 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.12 Million USD |
| MoneyControl | $8.12 Million USD |
| MarketWatch | $8.12 Million USD |
| marketcap.company | $8.12 Million USD |
| Reuters | $8.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ONCODES.PREC.MED. EO-34
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a rad… Read more